REGENXBIO Q1 net loss $66.7M ($1.53/share); cash $473.5M; pipeline advances

REGENXBIO Inc.

2023-Q1 EPS reported -$1.53 revenue$19,138,000

Cash, equivalents and marketable securities $473.5M as of Mar 31, 2023; runway into 2025.
Revenue $19.1M, down from $22.2M YoY mainly due to lower Zolgensma royalties ($16.1M vs $21.5M).
Net loss $66.7M ($1.53 per share) vs $76.7M ($1.79) YoY; R&D spend up to $58.5M.
Subretinal ABBV-RGX-314 pivotal trials expanded; regulatory submissions expected late 2025 to H1 2026.
RGX-202 Duchenne trial on track for initial data H2 2023; RGX-121 BLA filing planned in 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

REGENXBIO Inc. reported financial results for the quarter ended March 31, 2023.

Period: the quarter ended March 31, 2023
Result: reported results

Exact text from the filing

On May 3, 2023, REGENXBIO Inc. (the “Company”) issued a press release regarding its results of operations and financial condition for the quarter ended March 31, 2023.

View on SEC.gov

Browse all earnings releases →

REGENXBIO Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-017184

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.